Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 27;41(2):232–260. doi: 10.1210/endrev/bnz016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Endocrine Society 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 7. — Does BAT play any role in the response to leptin?

Data on the effects of leptin replacement on BAT function are less complete than the effects of leptin deficiency. (A) BAT weight is clearly reduced by leptin treatment and also total protein content is slightly decreased. Note that the tissue seems to go from an atrophied to an active state; however, this seems only to represent a transient lipolytic effect, as BAT is not recruited. (B) UCP1 mRNA has been reported to be increased following leptin treatment. This does not, however, translate into higher UCP1 total protein levels. (C) There are signs of increased sympathetic activity following leptin treatment, such as increased norepinephrine (NE) turnover. The response to adrenergic stimulation is, however, unaltered.